| Editor's Note: Fierce Biotech is taking a publishing break through the end of the year. Thank you for reading in 2021 and we'll see you back on January 4. Be sure to check www.fiercebiotech.com for the biggest headlines until then. Tomorrow, we'll send out a special issue highlighting the year's biggest stories. Enjoy your holiday season, and best wishes for the coming year. Featured Story | By Annalee Armstrong We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round of virtual dealmaking and more. read more |
| |
|---|
|
| 
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
Top Stories By Kyle LaHucik Biopharmas are not immune to the "Great Resignation" spurred by the pandemic, and drug developers will have to create new formulations to attract and retain talent, or at least improve current hiring practices, to stave off mass quitting in 2022. read more By Nick Paul Taylor Gyroscope Therapeutics has been spun this way and that in 2021, going from a $148 million raise to a failed IPO to a $40 million investment from Sanofi in quick succession. But Novartis has ensured the gene therapy startup has ended the year at the top of its arc by inking a $1.5 billion buyout. read more By Annalee Armstrong I’m sad to say that we at Fierce Biotech did not predict that 2021 would be the year that Alzheimer’s disease drug development blew up. But I’m here to correct the record and make such a prediction for 2022. read more By Kyle LaHucik The data are clear: White patients make up the majority in clinical trials. But the drug development industry—despite a lot of progress and an awareness among the largest pharmas out there—still leaves out many underrepresented populations in clinical testing. read more By Nick Paul Taylor Longevity and mental health biotechs take note: Korify Capital is putting together a $100 million venture fund targeting your space and is looking to build a portfolio of 15 to 20 companies across Europe, the U.S. and Israel. read more By Andrea Park Beginning in January, Americans will be able to visit a website where they can have the tests mailed directly to their homes at no charge. read more By Arlene Weintraub Novartis, Bristol Myers Squibb and Gilead are among the companies expected to bring in high revenues from their cell and gene therapies in 2022. And the late-stage pipeline could produce several more cancer CAR-Ts and gene therapies to treat a range of diseases. read more By Joseph Keenan Curebase, which is focused on siteless clinical trials, has joined the WCG Avoca Quality Consortium that boasts more than 175 pharma, biotech, clinical site and CRO organizations. read more By Heather Landi Deloitte predicts strong demand for wearable wellness technology in 2022 with 320 million consumer health and wearable wellness devices expected to ship worldwide in 2022. Here are other digital health sectors that could be hot areas for investment. read more By Eric Sagonowsky Through much of 2021, it seemed as if COVID-19 vaccines were enabling many countries to gently ease back into normalcy. Those hopes hit a rude awakening late in the year when the omicron variant emerged, and now industry leaders are forced—again—to quickly adapt. read more By Fraiser Kansteiner A second major HIV prospect has been put on hold, this time from Gilead Sciences. But unlike the recent halt on Merck's drug islatravir, which was related to a drop in trial patients' immune cell counts, Gilead's trial stop stems from a quality issue that could be swiftly resolved, one analyst says. read more By Fraiser Kansteiner CRISPR Therapeutics has quietly fired its head of R&D. Renowned chemist and beloved Caltech professor Robert Grubbs has passed away. And two Galapagos execs are flying the nest. read more Resources Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: BBK Worldwide New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
.jpg/GettyImages-1213432934+%281%29.jpg/d0460e33c88196b295dcc737409e0b16)
